ReviewBrain and behavior2026
Comorbidity Mechanism and Management of Chronic Low Back Pain and Major Depressive Disorder: From Neural Circuit Remodeling to Precision Medicine.
Review in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis review systematically elaborates multi-system interactive mechanisms underlying comorbid chronic low back pain (CLBP) and major depressive disorder (MDD), synthesizes recent advances in diagnosis, treatment, and management, and proposes precision medicine directions to address clinical challenges, including missed diagnosis, treatment resistance, and poor prognosis.
methodWe reviewed 86 studies published between 2015 and 2025 from the PubMed, Embase, and CNKI databases. We focused on basic research and clinical trials, integrating multi-omics data to construct mechanistic frameworks and therapeutic evidence.
resultThe comorbid pathogenesis of CLBP and MDD is driven by dysregulation of the "neural-immune-endocrine-gut-brain axis" network. Spinal dorsal horn N-methyl-D-aspartate (NMDA) receptor NR2B phosphorylation amplifies pain signals 2- to 3-fold, while anterior cingulate cortex (ACC)-insula connectivity correlates positively with depression severity. Microglial toll-like receptor 4/nuclear factor-κB (TLR4/NF-κB) activation increases cerebrospinal fluid interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) by 3.2- and 2.7-fold, respectively. Hypothalamic-pituitary-adrenal (HPA) axis dysfunction causes a flattened cortisol rhythm, with glucocorticoid receptor gene (NR3C1) hypermethylation reducing glucocorticoid sensitivity by 45%. Gut dysbiosis decreases short-chain fatty acids (SCFAs) by 30% and increases plasma lipopolysaccharide (LPS) by 2.3-fold, accompanied by abnormal proliferation of pro-inflammatory E. coli and Desulfovibrio as well as depletion of anti-inflammatory Prevotella. Duloxetine reduces visual analog scale (VAS) pain scores by 40% and Hamilton Depression Rating Scale (HAM-D) scores by 35% relative to placebo. Closed-loop spinal cord stimulation (SCS) improves treatment response rates to 68% compared with open-loop stimulation. Electroacupuncture at BL23/LR3 alleviates clinical symptoms in 75% of patients relative to sham acupuncture. At the 12-month follow-up, duloxetine's pain relief efficacy slightly declined from 40% to 38%, a phenomenon speculated to be linked to serotonin transporter upregulation. At the 1-year follow-up, closed-loop SCS efficacy decreases to 55%, which may be associated with secondary neural circuit re-remodeling. At the 6-month follow-up, electroacupuncture treatment carries a 22% symptom recurrence rate, which researchers hypothesize arises from secondary gut microbiota re-dysbiosis featuring reduced Prevotella abundance.
conclusionPathological progression of concurrent CLBP and MDD relies on multi-level remodeling of molecular, cellular, and systemic biological networks. Precision interventions targeting neural circuits, neuroinflammation, and the gut-brain axis, combined with multidisciplinary clinical collaboration, represent core strategies to break through current diagnostic and therapeutic bottlenecks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.